Adherence to adjuvant endocrine therapy after breast cancer in Sweden – a nationwide cohort study in 1-, 3- and 5-year survivors with a focus on regional differences
DOI:
https://doi.org/10.2340/1651-226X.2024.40575Keywords:
Adherence, Early Breast Cancer, Endocrin therapy, Adjuvant treatmentAbstract
Background and purpose: Adjuvant endocrine treatment (AET) is crucial in early oestrogen receptor (ER)-positive breast cancer (BC), providing reduced recurrence rate and increased overall survival. The aim of this study was to estimate AET adherence rates by age at diagnosis and region in Sweden.
Patients and methods: In total, 10,422 women diagnosed with ER-positive BC in 2008–2010 were identified in the Swedish National BC Registry. Information on prescriptions and dispensation of AET was gathered through record linkage to the Swedish Prescription Registry. 1, 3- and 5-year medication possession ratios (MPRs) were calculated. Good adherence was set as MPR ≥ 80%.
Results: The 1-, 3- and 5-year AET age-adjusted adherence rates were 94.4, 87.6 and 81.6%, respectively. The 1-, 3- and 5- year adherence rate was significantly highest in the South region (96.2, 90.5 and 86.2%). Regions with an oncologic clinic had higher adherence rate than regions without, 82.8% versus 75.5% at 5-year FU. Women at age 40–64 years (95.6, 89.9 and 84.1%) and 65–74 years at diagnosis (95.7, 89.5 and 84.6%) had significantly higher adherence rate than women ≥ 75 years at diagnosis (89.1, 79.2 and 68.3%).
Interpretations: Despite guidelines being national, there were significant differences in adherence between regions in Sweden. As the largest differences were between age groups invited and not invited to mammography screening intervention should focus on women < 40 and ≥ 75 years at diagnosis. Further studies are needed to find strategies to increase overall adherence to AET in early BC.
Downloads
References
Early Breast Cancer Trialists’ Collaborative G. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687–717.
https://doi.org/10.1016/S0140-6736(05)66544-0
Early Breast Cancer Trialists’ Collaborative G. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet. 2015;386(10001):1341–52.
https://doi.org/10.1016/S0140-6736(15)61074-1
Curigliano G, Burstein HJ, Winer EP, Gnant M, Dubsky P, Loibl S, et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol. 2017;28(8):1700–12.
https://doi.org/10.1093/annonc/mdx308
Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381(9869):805–16.
https://doi.org/10.1016/S0140-6736(12)61963-1
He W, Fang F, Varnum C, Eriksson M, Hall P, Czene K. Predictors of discontinuation of adjuvant hormone therapy in patients with breast cancer. J Clin Oncol. 2015;33(20):2262–9.
https://doi.org/10.1200/JCO.2014.59.3673
Aiello Bowles EJ, Boudreau DM, Chubak J, Yu O, Fujii M, Chestnut J, et al. Patient-reported discontinuation of endocrine therapy and related adverse effects among women with early-stage breast cancer. J Oncol Pract. 2012;8(6):e149–57.
https://doi.org/10.1200/JOP.2012.000543
Kuba S, Ishida M, Nakamura Y, Taguchi K, Ohno S. Persistence and discontinuation of adjuvant endocrine therapy in women with breast cancer. Breast Cancer. 2016;23(1):128–33.
https://doi.org/10.1007/s12282-014-0540-4
Murphy CC, Bartholomew LK, Carpentier MY, Bluethmann SM, Vernon SW. Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res Treat. 2012;134(2):459–78.
https://doi.org/10.1007/s10549-012-2114-5
Wigertz A, Ahlgren J, Holmqvist M, Fornander T, Adolfsson J, Lindman H, et al. Adherence and discontinuation of adjuvant hormonal therapy in breast cancer patients: a population-based study. Breast Cancer Res Treat. 2012;133(1):367–73.
https://doi.org/10.1007/s10549-012-1961-4
van Herk-Sukel MP, van de Poll-Franse LV, Voogd AC, Nieuwenhuijzen GA, Coebergh JW, Herings RM. Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment period of 5 years: a population-based analysis. Breast Cancer Res Treat. 2010;122(3):843–51.
https://doi.org/10.1007/s10549-009-0724-3
Hershman DL, Shao T, Kushi LH, Buono D, Tsai WY, Fehrenbacher L, et al. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat. 2011;126(2):529–37.
https://doi.org/10.1007/s10549-010-1132-4
Lundgren C, Lindman H, Rolander B, Ekholm M. Good adherence to adjuvant endocrine therapy in early breast cancer – a population-based study based on the Swedish Prescribed Drug Register. Acta Oncol. 2018;57(7):935–40.
https://doi.org/10.1080/0284186X.2018.1442932
Andrade SE, Kahler KH, Frech F, Chan KA. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf. 2006;15(8):565–74; discussion
575–67.
https://doi.org/10.1002/pds.1230
Makubate B, Donnan PT, Dewar JA, Thompson AM, McCowan C. Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality. Br J Cancer. 2013;108(7):1515–24.
https://doi.org/10.1038/bjc.2013.116
Seneviratne S, Campbell I, Scott N, Kuper-Hommel M, Kim B, Pillai A, et al. Adherence to adjuvant endocrine therapy: is it a factor for ethnic differences in breast cancer outcomes in New Zealand? Breast. 2015;24(1):62–7.
https://doi.org/10.1016/j.breast.2014.11.011
Huiart L, Dell’Aniello S, Suissa S. Use of tamoxifen and aromatase inhibitors in a large population-based cohort of women with breast cancer. Br J Cancer. 2011;104(10):1558–63.
https://doi.org/10.1038/bjc.2011.140
Weaver KE, Camacho F, Hwang W, Anderson R, Kimmick G. Adherence to adjuvant hormonal therapy and its relationship to breast cancer recurrence and survival among low-income women. Am J Clin Oncol. 2013;36(2):181–7.
https://doi.org/10.1097/COC.0b013e3182436ec1
Partridge AH, Wang PS, Winer EP, Avorn J. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol. 2003;21(4):602–6.
https://doi.org/10.1200/JCO.2003.07.071
Barlow L, Westergren K, Holmberg L, Talback M. The completeness of the Swedish Cancer Register: a sample survey for year 1998. Acta Oncol. 2009;48(1):27–33.
https://doi.org/10.1080/02841860802247664
Lofgren L, Eloranta S, Krawiec K, Asterkvist A, Lonnqvist C, Sandelin K, et al. Validation of data quality in the Swedish National Register for Breast Cancer. BMC Public Health. 2019;19(1):495.
https://doi.org/10.1186/s12889-019-6846-6
Interactive report: National Quality Register for Breast Cancer (In Swedish) 2024-04-01. Available from: https://statistik.incanet.se/brostcancer/
Stjarnfeldt. Breast cancer patients´s experiences and reflections regarding information about endocrine therapy and its side-effects – a focus group intervju. SOJ Nurs Health Care. 2015;1(1):1–8.
https://doi.org/10.15226/2471-6529/1/1/00102
Hershman DL, Kushi LH, Shao T, Buono D, Kershenbaum A, Tsai WY, et al. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol. 2010;28(27):4120–8.
https://doi.org/10.1200/JCO.2009.25.9655
Robb C, Haley WE, Balducci L, Extermann M, Perkins EA, Small BJ, et al. Impact of breast cancer survivorship on quality of life in older women. Crit Rev Oncol Hematol. 2007;62(1):84–91.
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2023 Anna De Jong, Anna Von Wachenfeldt, Lennarth Nyström, Anne Andersson
This work is licensed under a Creative Commons Attribution 4.0 International License.
